Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 9Ovarian Neoplasms 2Neoplasm Metastasis 2Lymphatic Abnormalities 2Lymphangioma, Cystic 2Lymphangioma 2Vascular Malformations 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Diseases, Vascular 1Recurrence 1Multiple Endocrine Neoplasia Type 1 1Melanoma 1Hyperglycemia 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1HER2-positive Metastatic Breast Cancer 1Genetic Diseases, Inborn 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Arteriovenous Malformations 1Advanced HER2+Breast Cancer 1Advanced Breast Cancer 1

Interventions

mirdametinib 1Everolimus 1Alpelisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Vascular Malformations × Alpelisib × 90 days × Clear all
NCT05983159 2026-05-05

TARGET-VM

Murdoch Childrens Research Institute

Phase 2 Recruiting
50 enrolled

Arteriovenous Malformations, Lymphangioma, Skin Diseases, Vascular, Lymphangioma, Cystic, Lymphatic Abnormalities, Vascular Malformations

Data powered by HemOnc (CC BY 4.0) Colophon âš¡